Gilead Sciences, Inc.
GILDNASDAQHealthcareDrug Manufacturers - General
As of Oct 22, 2026 close
- Market cap
- $195.39B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- 2.07%
- 52-week range
- $114.02$160.51
- Volume (live)
- -
- Avg. volume (3M)
- 5.97M
Gilead Sciences (GILD) Stock Price & Financial Analysis
Gilead Sciences Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $153.00 - $157.42 |
|---|---|
| 52-Week High | $160.51 |
| 52-Week Low | $114.02 |
| Open | $154.24 |
| Volume (last close) | 6.21M |
| Average Volume (3M) | 5.97M |
| Revenue (TTM) | 30.46B |
|---|---|
| Net Income (TTM) | -3.24B |
| Free Cash Flow (TTM) | 12.94B |
| EPS (TTM) | −$2.59 |
| Profit Margin | -10.64% |
| Operating Margin | 37.56% |
| Return on Equity (ROE) | -27.39% |
| Debt to Equity | 2.22 |
| Annual Dividend | $3.25 |
|---|---|
| Dividend Yield | 2.07% |
| Payout Ratio | 43.81% |
| Last Dividend Ex-Date | Sep 15, 2026 |
| Market Cap | 195.39B |
|---|---|
| Shares Outstanding | 1.24B |
| Price to Sales (P/S) | 6.42 |
| Price to Book (P/B) | 16.52 |
| EV/EBITDA | 16.08 |
| 50-Day MA | $147.70 |
|---|---|
| 200-Day MA | $138.35 |
| 1-Year Change | +30.19% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Gilead Sciences at a Glance
As of the Oct 22, 2026 close, Gilead Sciences (GILD) has a market capitalization of $195.39B. The stock trades at 6.4× sales. Over the trailing twelve months it lost $3.24B on revenue of $30.46B and generated $12.94B of free cash flow. Revenue grew 5.5% year over year.
As of its latest reported balance sheet, it holds $3.18B in cash and securities against $26.25B of debt, a net debt position of $23.07B.
Gilead Sciences pays a quarterly dividend totaling $3.25 per share a year, a 2.07% yield at the Oct 22, 2026 close, with a 44% payout ratio and 10 consecutive years of dividend increases.
The share price is up 30.2% over the past year. At $157.19 (the Oct 22, 2026 close) it sits near the top of its 52-week range of $114.02 to $160.51, above its 200-day moving average of $138.35.
Based on 23 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $160.00, 1.8% above the Oct 22, 2026 close.
Frequently Asked Questions About Gilead Sciences
What is the current stock price for GILD?
As of the Oct 22, 2026 close, GILD stock trades at $157.19. The 52-week range is $114.02–$160.51, with a day range of $153.00–$157.42.
What is the P/E ratio for GILD?
The P/E ratio (Price-to-Earnings) for GILD is shown in the Key Statistics section. This valuation metric helps compare Gilead Sciences, Inc. to industry peers.
Does GILD pay dividends?
Yes, Gilead Sciences pays a 2.07% annual dividend yield as of the Oct 22, 2026 close ($3.25 per share a year). The trailing twelve-month payout ratio is 43.8%. The most recent ex-dividend date was September 15, 2026.
What do analysts recommend for GILD?
Based on ratings from 23 professional analysts over the last 90 days, the consensus for GILD is Buy. The average 12-month price target is $160.00, a 1.8% upside from the Oct 22, 2026 close of $157.19.
What is the market cap of GILD?
As of the Oct 22, 2026 close, Gilead Sciences's market capitalization is $195.39B, classifying it as a large-cap company. Gilead Sciences operates in the Healthcare sector within the Drug Manufacturers - General industry.